Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This randomized clinical trial compares two systemic treatments for HER2-positive breast
cancer. The treatments are given either prior to breast surgery (as neoadjuvant treatment) or
after breast surgery (as adjuvant treatment). In the investigational group (Group A) the
study participants will receive a combination of two drugs directed at HER2 (two anti-HER2
antibodies) plus a chemotherapy agent (docetaxel) for a brief duration, and the patients
allocated to the comparator group (Group B) will be treated with chemotherapy plus one
anti-HER2 treatment (trastuzumab) for one year.